Whole Body Health & Wellness

Studies on the relevance of C15:0 to metabolic health and glucose control have shown the following:

• Mechanisms of action: AMPK, AKT, and PPAR alpha/delta activator
• Cell-based studies: Dose-dependent improvement in glucose uptake and insulin sensitivity
• In vivo studies: Lowered glucose, proinflammatory cytokines, and cholesterol
• Human prospective cohort meta-analyses: Lower risk of having or developing type 2 diabetes

Studies on the relevance of C15:0 to liver health have shown the following:

• Mechanisms of action: PPAR alpha/delta activator
• Cell-based studies: Dose-dependent anti-inflammatory and antifibrotic efficacy
• In vivo studies: Lowered liver inflammation, liver fibrosis, and liver iron deposition
• Human epidemiological studies: Lower liver fat, lower liver enzymes, less severe liver disease
• Randomized clinical trial: Achieving C15:0 levels > 5 ug/ml results in lower liver enzymes (ALT and AST)

Studies on the relevance of C15:0 to immune health have shown the following:

• Mechanisms of action: JAK-STAT and HDAC6 inhibitor, PPAR alpha/delta activator
• Cell-based studies: Dose-dependent anti-inflammatory activities
• In vivo studies: Lowered systemic, liver, joint, and gut inflammation
• Human epidemiological studies: Lower CRP

Studies on the relevance of C15:0 to heart health have shown the following:

• Mechanisms of action: AMPK activator & JAK-STAT inhibitor
• Cell-based studies: Dose-dependent anti-inflammatory activities in human vascular cells
• In vivo studies: Lowered inflammation and cholesterol
• Human epidemiological studies: Lower cholesterol, lower triglycerides, lower risk of hypertension, lower risk of cardiovascular disease, including coronary heart disease, lower risk of incident carotid plaques
• Randomized clinical trials: Lower LDL cholesterol, lower arterial stiffness (cfPWV)

Studies on the relevance of C15:0 to anti-cancer properties have shown the following:

• Mechanisms of action: JAK-STAT and HDAC6 inhibitor
• Cell-based studies: Dose-dependent anticancer activities with human cancer cell lines. Cell-based phenotypic profiling predicts C15:0 as having anticancer activities mimicking gemcitabine and paclitaxel
• In vivo studies: Smaller tumor size in rodents, improved upon gemcitabine alone
• Human epidemiological studies: Lower risk of having or developing certain types of cancers, including colorectal and breast cancer

Studies on the relevance of C15:0 to cognitive, mood & sleep health have shown the following:

• Mechanisms of action: Dose-dependent FAAH and MAO-B inhibitor
• Cell-based studies: Cell-based phenotypic profiling predicts C15:0 as having antidepressant activities mimicking bupropion
• Human epidemiological studies: Higher C15:0 levels associated with better cognitive scores among people with type 2 diabetes, as well as lower anxiety
• Randomized clinical trial: Women with MASLD who followed a low-calorie Mediterranean Diet and were supplemented with C15:0 daily for 12 weeks had the most significant decreases in anxiety and depression.